18 F-deoxy-glucose) is the current gold standard for PET imaging. 18 F-fluorothymidine), a PET imaging marker of proliferation, has been proposed as an alternative to FDG for the assessment of therapeutic response. We examined the therapeutic predictive value of FLT-PET and FDG-PET using CALU-6, a human, p53-null, non-small cell lung cancer cell line with comparison of combined targeted therapy, TRAIL and sorafenib, versus combined conventional chemotherapy, docetaxel and cisplatin. CALU-6 tumor-bearing nu/nu mice (n=46) were evaluated in 3 therapeutic trials measuring FLT and FDG prediction of tumor response at 72 h following initiation of daily combination therapy with targeted agents, TRAIL (200 µg i.v.) and sorafenib (30 mg/kg i.p.) and compared to conventional chemotherapeutics cisplatin (3 mg/ kg i.p.) and docetaxel (7.5 mg/kg i.p.). PET imaging response was compared to morphological and histological indicators of therapeutic response, including decreased vascu larity (in vivo AngioSense imaging and anti-CD31 staining), slowed tumor growth (caliper measurements), decreased cellular proliferation (Ki-67 staining) and increased apoptosis (TUNEL staining). Decreases in tumor accumulation of FLT (FLT MAX -30%, p=0.03) at 72 h post treatment were observed in response to TRAIL and sorafenib combination therapy resulting in smaller, less vascular, more apoptotic tumors. No similar reduction in tumor accumulation of FLT (FLT MAX -2%, p=0.67) was observed 72 h following initiation of cisplatin and docetaxel combination therapy, despite histological and morphological evidence of drug response. In contrast, tumor imaging with FDG did demonstrate a decrease in accumulation in both treatment groups, -21% (p=0.30) in response to cisplatin/ docetaxel and -8% (p=0.59) in response to TRAIL/sorafenib, but did not reach statistical significance. FLT, but not FDG, is predictive of therapeutic response to the targeted regimen TRAIL/sorafenib. However, FLT-PET may not predict therapeutic response to DNA damaging agents in p53-null tumors, likely due to loss of cell cycle control of thymidine kinase 1 (TK1). Thus, tumor imaging response by FLT may be limited in human tumors without functional p53.
Introduction
Lung cancer, which is predominantly p53 insufficient (1-3), is often diagnosed at an advanced stage with less than 1-year survival. A major barrier to improving these survival statistics stems from our current system of reliance on large changes in tumor size to assess therapeutic response, with typical posttherapeutic CT scan occurring months after therapy initiation (4) . Recently, PET imaging radiotracers of metabolism have been explored as early markers of therapeutic response in malignancy. FDG, a PET radiotracer of glucose metabolism, is currently the clinical radiotracer of choice for oncologic PET applications.
While FDG-PET is highly sensitive and can serve as a marker of therapeutic response, specificity suffers and is particularly limited in certain therapeutic settings such as following radiation therapy, surgery, infection and talc pleurodeisis and in certain anatomic locations including the brain, mediastinum, heart and liver. FLT ( 18 F-labelled thymidine), is a PET (positron emission tomography) imaging thymidine analog radiotracer, and well documented surrogate marker of cellular proliferation, which has shown promise as an early therapeutic response indicator. FLT-PET tumor response to therapy, correlating ultimately with morphological tumor response, has been demonstrated as early as 24-48 h following chemotherapy initiation, both in animal models (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) and clinical trials (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) .
In order to implement FLT into clinical practice, triaging chemotherapies early after induction, the variables impacting FLT accumulation in tumors must be fully understood. FLT enters the cell using cell membrane-associated nucleoside transporters then is retained in the cell after phosphorylation by thymidine kinase 1 (TK1), a tightly regulated enzyme and rate-limiting step of the DNA salvage pathway, vital for maintaining tumor thymidine levels. Since thymidine is not a component of RNA, tumor accumulation of FLT is a reflection of DNA synthetic rate only and correlates exceptionally well with TK1 activity and percentage of cells in S phase of the cell cycle. TK1 is virtually absent in non-dividing cells (26) .
In this report, we examine changes in tumor accumulation of FLT and FDG following therapy in a xenograft mouse model of p53-null human non-small cell lung cancer (NSCLC) using CALU-6. PET imaging tumor response is evaluated after 72 h of therapy with either a conventional, DNA-damaging chemotherapy regimen or targeted regimen. We chose CALU-6, a p53-null human NSCLC line which has been previously characterized as sensitive to monotherapy with conventional therapies cisplatin (27) (28) (29) (30) (31) , a DNA damaging agent, and docetaxel (32, 33) , an anti-tubulin agent, in order to examine the response of FLT to traditional chemotherapeutics. Cisplatin and docetaxel combination therapy is a currently accepted conventional first-line therapy for NSCLC.
CALU-6 cells are also very sensitive to combination therapy with the targeted agents TRAIL (TNF-related apoptosis inducing ligand), a naturally occurring death-receptor agonist, and sorafenib, a multi-targeted tyrosine kinase inhibitor (34) . Both death receptor agonists and sorafenib have demonstrated evidence of efficacy in NSCLC and are currently in clinical trials (35) (36) (37) (38) (39) . Examination of p53-null tumor FLT response to the targeted therapies TRAIL and sorafenib provides an opportunity to study FLT response in a system known to be therapeutically effective in vitro and not reliant on DNA-damage as the principle mechanism of action.
Materials and methods
Cell lines and cell culture. CALU-6, a p53-null human non-small cell lung cancer cell line was newly purchased from American Type Culture Collection (ATCC, Manassas, VA).
Cells were maintained in a humidified sterile environment with 5% CO 2 , 37˚C RPMI-medium supplemented with 10% heat-inactivated fetal calf serum with 1% penicillin and streptomycin (CM). Passage of cell lines was performed at 1:5 dilution after detachment using sterile 0.05% trypsin-EDTA solution.
Chemotherapeutics. His-tagged-TRAIL was synthesized via plasmid expression as previously described (40) and purification and stored as a 1 mg/ml stock in dPBS at -20˚C. Sorafenib was synthesized in powder, free base form for use in our laboratory as previously described (41) . Sorafenib was dissolved in 100% DMSO and stored at -20˚C as a concentrated stock for in vitro studies. For in vivo studies, sorafenib was dissolved in a Cremaphor EL solution (Sigma-Aldrich, St. Louis, MO), made freshly for each daily dose. Cisplatin powder was purchased from (Sigma-Aldrich) and prepared freshly in sterile dPBS prior to each injection. Docetaxel (10 mg/ml solution) was obtained from the University of Pennsylvania Abramson Cancer Center pharmacy then diluted in the 13% ETOH vehicle solution.
In vitro cell death assays. Cells were harvested from culture with 0.05% trypsin-EDTA, washed in CM, plated at 0.6x10 6 / well in a sterile 6-well plate and incubated at 37˚C, 5% CO 2 for 18-24 h to allow attachment of cells to the wells. Sorafenib (diluted in CM from 32 mM stock in DMSO) was then added to the appropriate wells for a total of 4 ml CM and incubated for 16-22 h. Cells treated with TRAIL (his-TRAIL, diluted in CM) were incubated with TRAIL for 4 h with or without pre-incubation with sorafenib, and added to the appropriate wells at either 50 or 100 ng/ml.
For wells not containing sorafenib, culture medium was treated with 0.1% DMSO to control for the possible effects of DMSO on cell viability. After incubation with treatment, cells were washed with cold sterile dPBS, fixed (10% methanol/10% acetic acid solution) for 10 min, stained with Coomassie blue for 3 min, then rinsed with distilled water and allowed to air-dry.
Propidium iodide FACS.
After incubations with chemotherapies in a 60-mm tissue culture dish, supernatants and adherent cells were removed using 0.5% trypsin-EDTA, washed with cold dPBS and cell pellets resuspended in a 75% ETOH solution (4˚C) for a period of overnight to 1 month at 4˚C. On the day prior to FACS analysis, cells were washed with cold dPBS, permeabilized with 0.5 M phosphocitrate acid solution, then resuspended in a propidium iodide solution (RNAse/PI in dPBS) and allowed to incubate overnight at 4˚C. The cells were then sorted by FACS the next day and the subG 1 fraction measured.
Xenograft formation. Prior to the use of animal models, protocol approval was obtained by the Institutional Animal Care and Use Committee (IACUC) at the University of Pennsylvania. Two-month old female nu/nu mice (Crl:NUFoxn1nu, Charles River Laboratory, Wilmington, MA) were injected subcutaneously in each flank with 2x10 6 CALU-6 cells suspended in a sterile, endotoxin-free 50% Matrigel solution. After therapy/imaging completion, mice were euthanized with ketamine i.p. followed by cervical dislocation.
In vivo therapeutic trials. Following xenograft formation, FLT-PET or FDG-PET was performed prior to initiation of chemotherapy (Fig. 1) In vivo trials were conducted in order to assess the dynamics of FLT-PET uptake in CALU-6 tumor-bearing xenografts treated with TRAIL and sorafenib, for an average therapeutic period of 15 days. Either FLT-PET or FDG-PET was performed at baseline and 72 h after therapy initiation. At the completion of the therapeutic period, mice were euthanized and tumors excised and preserved for histology in a 4% paraformaldehyde solution. Tissues were then paraffin-embedded, sectioned and stained with hematoxylin and eosin, antibody against Ki-67 nuclear antigen (Dako, Carpinteria, CA), anti-CD31 (Dako), and TUNEL (Roche Diagnostics Corp., Indianapolis, IN). If tumors became too large to treat, intravenous access became limited, or mice demonstrated signs of distress, mice were sacrificed immediately as per IACUC regulations. Out of a total of 46 xenografted mice, only 1 died prior to completion of the trial, this mouse was in the treatment group during the pilot trial of TRAIL and sorafenib therapy.
A pilot trial of 8 CALU-6 tumor-bearing mice receiving daily TRAIL/sorafenib therapy (n=4) or untreated (n=4) was conducted in order to assess success of the in vivo anti-angiogenic therapy with the TRAIL/sorafenib regimen. At the completion of the therapeutic period, and prior to sacrifice, tumors were imaged with the optical imaging agent AngioSense (VisEn Medical, Inc., Bedford, MA) as per vendor specifi cations. Once tumor response to sorafenib/TRAIL therapy was established in vivo, a cohort of 25 tumor-bearing mice were allocated to one of the following groups: cisplatin/docetaxel (n=8); TRAIL/ sorafenib (n=8); untreated control (n=5); or vehicle control (n=4). In addition to following therapeutic response by in vivo tumor imaging and ex vivo histology, tumors were also followed by caliper volume measurements using the modified ellipsoid formula: tumor volume = 1/2(length)(width) 2 (42) . Finally, to assess whether FLT-PET or FDG-PET could predict treatment failure, despite inherent CALU-6 sensitivity to therapy, tumors were allowed to reach ~2-3 times the size of optimal treatment size (330-350 mm 3 rather than 100-150 mm 3 ); we have observed in our laboratory that growth of tumors to this size significantly hinders therapeutic efficacy in xenograft models of malignancy. Tumor-bearing mice were then assigned to either treatment with TRAIL/sorafenib (n=7) or no treatment (n=6) groups. One of the mice from each the untreated and treated groups was dropped from the data calculations due to poor tumor growth.
PET imaging and image interpretation. FLT and FDG radiotracers were synthesized in the PET Cyclotron Facility at the University of Pennsylvania. After anesthesia with inhaled isofluorane in O 2 (3% induction, 1.5% maintenance), mice were injected with 200-250 µCi of FLT or FDG then allowed to recover from the anesthesia during the 60-min uptake time allowed for radiotracer accumulation. At 60 min post-injection, mice were anesthetized and imaged for a 15-min static acquisition on the small animal PET scanner (A-PET, built in collaboration with Philips Medical Systems) located at the University of Pennsylvania Small Animal Imaging Facility. This system has very high spatial resolution (~2 mm), operates exclusively as a fully 3D instrument with very high sensitivity and large field-of-view of 12 cm in both axial and transverse directions.
Images were reconstructed with the manufacturer software and tumor volumes of FLT quantitated with the freely available Amide 3D software (Medical Image Data Examiner (Amide), LG Software Innovations), which allows for multiplanar analysis of the tumor volume. A ROI (region of interest) was traced around the tumor volume creating a 3D ROI that could be carefully sculpted to the 3D tumor perimeter and visually inspected in the axial, coronal and sagittal planes. Once 3D tumor volume is created, the Amide software provides statistical data analysis including ROI volume (mm 3 ), mean counts/pixel, max PET counts/pixel and standard deviation of tumor counts/ pixel. PET values generated by the A-PET machine are absolute pixel counts. Absolute tumor counts were normalized to flank muscle (tumor ROI pixel value/thigh muscle ROI pixel value). This normalization provides a correction factor for subtle differences in PET tumor uptake time and dose.
Optical imaging. At 48 h prior to sacrifice, each mouse was anesthetized with i.p. ketamine and injected with 100 µg of AngioSense IV (VisEn Medical, Inc.) by tail vein and a time course of imaging tumor imaging with AngioSense (preinjection, 20 min, 6, 24 and 48 h) was acquired on the Maestro (CRI, Woburn MA), with appropriate excitation and absorbance filters. The AngioSense signal was acquired as an image cube data file, then dye signal was unmixed from background autofluorescence using the CRI post-processing software. Immediately after euthanasia, the tumors were excised and AngioSense signal measured directly from the tumor on the Xenogen IVIS system using the ICG channel. AngioSense imaging was performed for the pilot trial of TRAIL/sorafenib therapy to evaluate therapeutic response.
Histological analysis. After euthanasia, tumors were promptly excised, weighed, immersed in a 4% paraformaldehyde solution and allowed to incubate overnight at 4˚C. The tissues were then removed and placed in a solution of 70% ethanol for 24 h to 2 weeks at 4˚C. Tissues were then paraffin-embedded, sectioned into 5 µm slices and mounted onto slides by the GI Morphology Core, University of Pennsylvania. Immunohistochemistry was performed at the Children's Hospital of Philadelphia Research Institute, Pathology Core. TUNEL staining was performed using TUNEL enzyme and TUNEL label (Roche Boehringer-Mannheim, Indianapolis, IN).
TUNEL stained tissues were viewed (x20 magnification) under a Nikon E600 microscope (Nikon, Japan), equipped with fluorescent optics, and 5 randomly acquired 22 mm fieldof-view (FOV) images were obtained for each slide. Two At 72 h following initiation of therapy, a post-treatment PET was performed. Therapy was continued for ~2 weeks, followed by euthanasia and histological examination of tumor tissues.
images were captured for each FOV optimized for each spectrum for TUNEL staining (absorption MAX 365 nm, emission MAX 460 nm; green filter) and DAPI counterstaining (absorption MAX 358 nm, emission MAX 461 nm; blue/cyan filter). Nuclear TUNEL and DAPI staining positivity was then quantitated using Image J software (Image Processing and Analysis in Java, National Institute of Health, Bethesda, MD). The % TUNEL-positive nuclei was normalized using % positive DAPI nuclear staining for each FOV. The mean normalized % TUNEL staining value of the 5 acquisitions for each tumor was then calculated. Tissues stained with anti-Ki-67 (Dako, Carpinteria, CA) were developed with horseradish-peroxidase linked antibodies and the entire slide for each tumor was scanned into digital format. The % positive nuclear staining was calculated using the semi-automated Aperio scanscope software.
Statistical analysis. Quantitative data were analyzed, including t-test, average, linear regression and correlation, using the EXCEL Spreadsheet Data ToolPak (Microsoft Office). For paired data sets, pre and post PET imaging data, a paired, 2-tailed t-test was performed and p-value obtained. For unpaired data sets, comparisons between treatment groups, an un-paired, 2-tailed t-test was performed. An α of 0.05 was employed to determine significance.
Results
In this study we sought to evaluate whether FLT-PET could be used as a predictor of therapeutic success or failure in vivo in the setting of a p53-null malignancy. The p53-null human non-small cell lung cancer (NSCLC) line CALU-6 is highly sensitive to combination therapy with sorafenib and TRAIL in vitro (34) . In this study we confirmed in vitro sensitivity of CALU-6 to combination therapy with TRAIL and sorafenib (Fig. 2) then further demonstrated this sensitivity in vivo, for ability to induce apoptosis (Fig. 3) , inhibit angiogenesis (Fig. 4) and effect growth inhibition. In vivo therapeutic response of CALU-6 to TRAIL and sorafenib therapy thus was confirmed by the observation of markedly increased apoptosis by TUNEL staining of treated tumor tissues (Fig. 3) , decreased caliper measured tumor volumes, decreased tumor accumulation of AngioSense (Fig. 4) , a blood pooling agent and decreased tissue vessel density by anti-CD31 staining (Fig. 4) .
P53-null CALU-6 tumor decreased accumulation of FLT at 72 h correlates with growth inhibition in the TRAIL/sorafenib
group. TRAIL/sorafenib therapeutic response of CALU-6 tumors was predicted by a decrease in tumor accumulation of FLT at 72 h of therapy relative to baseline. In the pilot trial (n=8) of TRAIL/sorafenib therapy, the tumor overall FLT MAX had dropped to -17%, corresponding to actual tumor regression with a 52% decrease in mean tumor volume observed at the end of the therapeutic period. By comparison, untreated tumors demonstrated a rise in FLT MAX of 9%, corresponding to a mean change in tumor volume of 206% (p=0.05).
A cohort of 25 CALU-6 bearing mice were then allocated into the following treatment groups: targeted therapy with TRAIL/sorafenib (n=8); conventional DNA-damaging therapy with cisplatin and docetaxel (n=8); untreated control (n=5); and vehicle-only control (n=4). One-half of each treatment group was serially imaged only with FLT-PET while the other half was imaged only with FDG-PET. After 72 h of daily TRAIL/sorafenib combination therapy, the mean tumor FLT MAX dropped to -30% (±8%, p=0.03) relative to baseline (Fig. 5) corresponding to 79% tumor growth inhibition (±27%, p=0.02) relative to untreated controls. Surprisingly, therapy with Cremaphor EL vehicle alone resulted in a growth inhibition of 51% (p=0.05) which correlated to elevated apoptosis with subsequent TUNEL staining of excised tumor. This is a previously reported property of Cremaphor EL (43) and tempers conclusions regarding the efficacy of TRAIL/sorafenib therapy, the establishment of which is not the goal of this study. It would be useful to explore this apparent anti-tumor effect since Cremaphor EL is a commonly used vehicle for sorafenib in animal imaging.
Imaging and volume measurements correlated with histological markers of tumor response to therapy. TUNEL staining of excised tumors at end of therapy revealed increased nuclear staining for nicked DNA, indicating cellular commitment to apoptosis, in the TRAIL/sorafenib group relative to untreated controls (71% versus 18%, p=1.7E-07). Ki-67 staining of excised tumors did not demonstrate suppression of proliferation in the TRAIL/sorafenib treatment group relative to the untreated control group (80% versus 80% respectively, p=0.9).
P53-null CALU-6 tumor did not demonstrate an imaging response with FLT-PET response at 72 h despite growth inhibition in the cisplatin/docetaxel group.
Combination therapy with conventional chemotherapeutics, cisplatin and docetaxel (n=8) was compared to PBS vehicle (n=2) and the untreated control group (n=5). Cisplatin/docetaxel therapy, dosed weekly, resulted in no significant change in tumor FLT MAX -2% (STD±7%, p=0.3) at 72 h following therapy initiation (Fig. 6 ). This lack of FLT tumor response significantly underestimated the actual mean growth inhibition of 46% (STD±30%, p=0.002). The cisplatin/docetaxel mediated growth inhibition of 46% was less robust (p=1.19 E-05) than that observed in the TRAIL/sorafenib group (79%).
Cisplatin/docetaxel treated CALU-6 tumor histology demonstrated elevated proliferation post therapy. Ki-67 staining of excised CALU-6 tumors revealed slightly elevated cellular proliferation in cisplatin/docetaxel treated tissues relative to TRAIL/sorafenib (86% versus 80%, p=0.03). TRAIL/sorafenib therapy did not appear to impact proliferation relative to untreated controls (80% versus 80%, p=0.89). However, tissues were harvested 24 h after last TRAIL/sorafenib dose and 4 days after the weekly cisplatin/docetaxel dose. It is possible that cellular proliferation had begun to recover at the point of tumor excision. In addition, cisplatin/docetaxel has been previously demonstrated to transiently stimulate TK1 activity, a known response to DNA damage.
Both TRAIL/sorafenib and cisplatin/docetaxel groups demonstrated elevated apoptosis in treated CALU-6 tumors.
TUNEL staining of excised cisplatin/docetaxel treated tumors revealed increased % positive cellular nuclear staining for nicked DNA, indicating commitment to programmed cell death relative to untreated controls (40% versus 18%, p=0.01) although not as robust as that induced with TRAIL/sorafenib therapy (71% versus 18%, p=0.0001). The difference in % TUNEL positivity between cisplatin/docetaxel and TRAIL/ sorafenib groups was significantly different (40% versus 71%, p=0.002). Interestingly, the Cremaphor EL control exhibits elevated TUNEL positivity indicating a strong pro-apoptotic characteristic of the vehicle itself (90% versus 18%, p=1.7E-06) and calling into question its utility as a chemotherapeutic vehicle. However, since testing of chemotherapeutic efficacy was not the goal of this study and the Cremaphor EL vehicle group small (n=2), this phenomenon merits further investigation. Interestingly, there is a report in the literature supporting the anti-tumor effects of Cremaphor EL (43) .
In the setting of treatment failure, tumor FLT Max follows actual tumor response rather than inherent tumor cell sensitivities. In order to create a treatment failure, we allowed the CALU-6 tumors to reach a size of 330-350 mm 3 , ~2-3 times that of the usual starting tumor volume (100-150 mm 3 ). In our laboratory, we have observed that when xenografted human tumors are allowed to grow to large sizes, they are more refractory to treatment, independent of inherent sensitivities (unpublished data). Using this treatment failure model, the TRAIL/sorafenib treatment group (n=7) and untreated control (n=6) both demonstrated tumor growth with the exception of one mouse in the untreated group that did not grow. The data from this one mouse was excluded from the results. Interestingly, tumor uptake of FLT did not decrease in response to TRAIL/sorafenib therapy, despite inherent sensitivity, but rather reflected the treatment failure observed by lack of growth inhibition. FLT MAX was increased by +11% (STD±3%, p=0.06) in the TRAIL/ sorafenib treatment group corresponding tumor growth of 302% (p=0.001). FLT MAX in the untreated group was -7% (STD±11%, p=0.5) with mean tumor growth of 217% (p=0.011) in the untreated group.
CALU-6 tumor uptake of FDG was variable following treatment with cisplatin/docetaxel and TRAIL/sorafenib therapy.
In therapeutic trials of TRAIL/sorafenib and cisplatin/ docetaxel, overall tumor uptake of FDG MAX did decrease posttherapy by as much as -49% (Figs. 5 and 6 ). However, there was variability in this imaging response leading to an overall change in uptake -8% (p=0.6, STD±36%) and -21% (p=0.3, STD±36%) for TRAIL/sorafenib and cisplatin/docetaxel therapy, respectively. In the model of treatment failure, there was a non-statistically significant overall decrease in FDG uptake in the TRAIL/sorafenib and untreated group of -8% (p=0.4, STD±39%) and -17% (p=0.2, STD±43%), respectively.
Discussion
Cellular proliferation, characteristically high in malignancy, requires a steady intracellular pool of deoxynucleotidetriphosphates (dNTPs). Of these dNTPs, thymidine is specific to DNA synthesis and its metabolism is tightly regulated by cell cycle control mechanisms which source thymidine through two pathways, de novo synthesis, regulated by thymidylate synthase (TS), and the salvage pathway, regulated by thymidine kinase (TK1) (44) . TK2, active in the mitochondria, is not cell cycle restricted. FLT, an 18 F analogue of thymidine, exploits the salvage pathway upon which most malignancies are reliant and has a predilection for TK1 rather than TK2 (45) . Under wild-type p53 conditions, DNA damage leads to p53-mediated negative regulation of TK1 followed by halt of cell cycle progression at the G 1 /S interface which leads to either cell death or senescence (46, 47) . This cell-cycle regulation of FLT accumulation, favorable imaging properties and promising preclinical and clinical trial data have led to intense interest in this radiopharmaceutical as an early indicator of therapeutic response in oncology.
However, the normal relationships between cell cycle progression and TK1 activity are lost in the setting of p53 deficiency. With loss of functioning p53, subsequent DNAdamage results in halting of the cell cycle progression at the G 2 /S checkpoint, rather than G 1 /S checkpoint, allowing accumulation of TK1 in S-phase (47) , which potentially limits the utility of FLT to predict therapeutic response in p53-null tumors (48, 49) . Given that altered p53 function is an extremely common tumor phenotype in general (50) and in NSCLC specifically (1) (2) (3) this becomes an important variable to be considered for FLT-PET to successfully enter clinical management.
Our data demonstrate that p53-null NSCLC CALU-6 xeno-grafts treated with cisplatin/docetaxel combination therapy, fail to elicit a predictive drop in FLT accumulation at 72 h following therapy implementation and do not reflect end-of-therapy growth inhibition and apoptosis relative to untreated controls. Given that imaging is performed before significant therapy induced morphological effects, such as anti-angiogenic activity or tumor shrinkage, are likely to be seen in the xenograft tumors, this discrepancy between imaging therapeutic response prediction and actual tumor response seems most likely either due to a failure of FLT to predict response or suboptimal timing of FLT measurement relative to last delivered therapeutic dose, thus missing the nadir in tumor proliferation.
The failure of FLT to predict therapeutic response in cisplatin/docetaxel therapy may stem from impaired function of p53 in CALU-6. Loss of p53 mediated DNA-damage induced G 1 /S checkpoint activation would allow cell cycle progression into S-phase, despite DNA-damage, allowing accumulation of TK1, and hence FLT, as previously described in other systems (47) . Furthermore, the S/G 2 block would halt cell cycle preventing the downregulation and degradation of TK1 seen in G 2 . This hypothesis is supported by the fact that we also did not see suppression of Ki-67 nuclear staining in cisplatin/docetaxel treated tumors, despite the evidence of increased apoptosis and tumor growth inhibition. The Ki-67 nuclear antigen, while not expressed in the resting (G 0 ) state, is expressed in the four active stages of the cell cycle, G 1 , S, G 2 and M.
Further study is needed with p53 wild-type controls to assess whether cisplatin/docetaxel is able to halt cell cycle progression appropriately in the presence of functional p53. Although a different chemotherapeutic, in vitro exposure to doxorubicin causes p53-null tumor cells to increase TK1 levels 8-36 h following exposure and sustain elevated TK1 levels until 42-48 h after dosing, allowing expansion of the TTP pool, recovery from chemotherapy induced DNA damage and reentry into mitosis (47) . This DNA damage-induced TK1 induction in p53-null cells has been demonstrated to be higher than p53-wild type tumors as a result of S/G 2 checkpoint activation with G 2 arrest (47). It is important to further explore the possible impairment of FLT in the setting of p53-deficiency since this would present a major problem due to the prevalence of the p53-deficient phenotype in clinical practice.
Alternatively, it is possible that due to the weekly dosing schedule of cisplatin/docetaxel, we have missed the maximal impact on cellular proliferation and allowed some degree of recovery from DNA-damage. FLT-PET was performed 72 h after the 1st weekly dose of cisplatin/docetaxel, both of which have plasma t 1/2 on the order of minutes to hours although cisplatin does have a prolonged protein-bound state. In the clinical setting, therapy with these agents is predicated on fast-acting and sustained DNA-damage allowing for weekly dosing in cancer therapy. However, there is pre-clinical literature suggestive that proliferation may begin to recover in 1-2 days rather than a week. For example, the dose-dependent impact of combination cisplatin/docetaxel therapy on proliferation was found to be maximal at 24-48 h in the osteosarcoma cell line HOS-8603 in vitro (51) and murine radiation-induced fibrosarcoma (RIF-1) tumors treated with cisplatin result in TK1 protein levels that fall by 24 h and recover to control levels by 48 h (13). In support of the 72-h post-treatment window prior to FLT measurement, the p-53 wild-type human squamous cell carcinoma cell line OS-1 demonstrated decreased FLT accumulation following exposure to cisplatin, in vitro, which continued to decrease at 72 h post-exposure (52) . Thus the kinectics of cisplatin/docetaxel and TRAIL/ sorafenib therapy impact on proliferation is an important variable to be considered in the evaluation of FLT as a marker of therapeutic response and will be the study of future work in our laboratory.
Interestingly, while tumor accumulation of FLT declined in TRAIL/sorafenib treated tumors, ultimately correlating with end of therapy marked growth inhibition, decreased tumor angiogenesis, and robust apoptosis, the % Ki-67 positive nuclear staining of these treated tumors did not decline. We propose two possibilities for this observation. First, sorafenib and TRAIL both have short half-lives with plasma t 1/2 on the order of 3-4 h and 5 min respectively. As a result in human clinical trials, sorafenib is dosed twice daily and TRAIL is given by continuous i.v. infusion. Therefore, it is possible that TRAIL/sorafenib therapy does transiently hinder proliferation which then recovers as the drug is rapidly eliminated. Our PET examinations were performed on the same day as TRAIL/sorafenib drug dosing whereas tumors were collected for histology approximately 18-24 h following the last dose of chemotherapy, potentially allowing for recovery of proliferation in viable cells. Secondly, sorafenib is a muti-targeted tyrosine kinase inhibitor with known activity against an increasing range of important targets including RAF/MEK/ERK pathway, PDGFR, c-kit, FLT-3, VEGFR, TGF-α among others. It is possible that the observed drug-induced decreases in FLT accumulation is a result of a block or aberration in thymidine metabolism upstream of TK1 or due to a mechanism totally independent of the DNA salvage pathway and without a direct impact on proliferation.
In conclusion, we propose that FLT accumulation may not be a reliable indicator of treatment success in the setting of a p53-null malignancy. Our results also highlight the need for further characterization of the relationship between the p53 status and predictive ability of FLT-PET and the impact of differences in treatment drug pharmacology on measurement of tumor FLT response in order to maximize the utility of this powerful molecular imaging tool.
